ABEL [Regulatives / Guidelines]

posted by nobody – 2014-11-19 17:05 (4236 d 10:07 ago) – Posting: # 13886
Views: 15,994

Why not interchangeable when MA was granted based on BE-studies for at least one formulation? Could you provide some details on the reasons? Thanx nobody

PS: Found somefink interesting, a strange company called BEBAC has apparently been digging deep into methylphenidate in the past...

http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Methylphenidate_Hexal/WC500156885.pdf

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
123 visitors (0 registered, 123 guests [including 13 identified bots]).
Forum time: 04:12 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5